In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Juno Therapeutics' IPO nets $283mm

Executive Summary

Just one year after its launch, Juno Therapeutics Inc. (chimeric antigen receptor T-cell (CART) technology for cancer drug development) netted $283mm through its initial public offering of 12.7mm shares (including the overallotment) at $24. The IPO (one of the largest for a US biopharma company in 2014) was greatly upsized: after filing in November, Juno set an initial range earlier this month of 9.25mm shares at $15-18, and a few days before pricing increased the potential per-share price to $21-23.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies

Advertisement
UsernamePublicRestriction

Register